Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: Fc epsilon RI signaling pathway (mmu04664)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
Akt1
KLA  ATP  ATP+KLA
NM_009652 thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] KLA .80 .80 .75 .75 .71 .70 .82
ATP 1.00 1.02 .76 .85 .76 .68 .84
KLA/ATP .82 .80 .64 .68 .67 .61 .72
Akt2
KLA  ATP  ATP+KLA
NM_007434 thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] KLA 1.45 1.49 1.81 1.61 1.83 1.17 .92
ATP 1.12 1.12 1.00 1.28 1.20 .94 1.06
KLA/ATP 1.48 1.70 1.69 1.58 1.57 1.32 1.27
Akt3
KLA  ATP  ATP+KLA
NM_011785 thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] KLA 3.42 3.45 5.31 5.16 4.65 3.80 2.12
ATP 1.12 1.22 1.10 1.37 1.02 1.11 1.56
KLA/ATP 3.72 4.17 4.62 4.64 2.74 2.05 3.82
Btk
KLA  ATP  ATP+KLA
NM_013482 Bruton agammaglobulinemia tyrosine kinase (Btk), mRNA [NM_013482] KLA 1.10 1.24 1.01 1.33 1.07 1.27 1.01
ATP .95 1.05 .86 .97 .66 .72 .82
KLA/ATP 1.14 1.35 1.12 1.52 .96 .70 .82
Csf2
KLA  ATP  ATP+KLA
NM_009969 colony stimulating factor 2 (granulocyte-macrophage) (Csf2), mRNA [NM_009969] KLA 1.44 1.53 1.38 1.37 1.15 1.21 1.14
ATP 1.01 1.02 1.85 9.73 2.64 1.90 1.14
KLA/ATP 1.49 1.84 2.14 2.80 1.67 1.36 1.35
EG629860
KLA  ATP  ATP+KLA
M17953 gb|Mouse Ig rearranged H-chain V-region mRNA VJ1 [M17953] KLA .96 1.05 1.03 1.08 1.08 1.02 .98
ATP .97 .99 1.05 1.10 .95 .94 .91
KLA/ATP .96 .94 .97 1.04 .97 1.01 .89
Fcer1a
KLA  ATP  ATP+KLA
NM_010184 Fc receptor, IgE, high affinity I, alpha polypeptide (Fcer1a), mRNA [NM_010184] KLA 1.14 .98 1.02 1.09 1.00 1.00 .96
ATP 1.04 1.03 1.07 .97 1.04 1.01 1.06
KLA/ATP .94 .98 1.09 1.04 1.06 .94 .95
Fcer1g
KLA  ATP  ATP+KLA
J05020 gb|Mouse mast cell high affinity IgE receptor (Fc-epsilon-RI) gamma subunit mRNA, complete cds. [J05020] KLA 1.41 1.43 1.53 1.61 1.91 2.07 2.49
ATP 1.13 1.21 .88 1.25 1.06 .92 1.45
KLA/ATP 1.64 1.64 1.25 1.84 1.45 1.39 2.32
Fcer1g
KLA  ATP  ATP+KLA
NM_010185 Fc receptor, IgE, high affinity I, gamma polypeptide (Fcer1g), mRNA [NM_010185] KLA 1.49 1.54 1.48 1.62 2.18 2.06 2.35
ATP 1.10 1.16 .78 1.00 .90 .98 1.18
KLA/ATP 1.48 1.67 1.26 1.71 1.33 1.40 2.13
Fyn
KLA  ATP  ATP+KLA
U70324 Fyn(T) (L-fyn(T)) mRNA, complete cds. [U70324] KLA 1.23 1.27 1.31 1.27 1.31 .87 .48
ATP .88 .71 .66 .75 .90 1.28 .51
KLA/ATP 1.12 1.01 .94 .84 1.25 1.51 .53
Gab2
KLA  ATP  ATP+KLA
NM_010248 growth factor receptor bound protein 2-associated protein 2 (Gab2), mRNA [NM_010248] KLA 1.01 1.04 1.04 1.02 1.12 1.16 1.14
ATP 1.02 1.06 1.00 1.13 1.16 1.19 1.23
KLA/ATP 1.06 1.05 1.03 1.02 1.03 1.04 1.29
Grb2
KLA  ATP  ATP+KLA
NM_008163 growth factor receptor bound protein 2 (Grb2), mRNA [NM_008163] KLA .92 .88 .90 1.27 1.43 1.22 1.00
ATP 1.02 .83 .51 .42 .92 .70 .57
KLA/ATP .84 .77 .61 .56 1.56 1.49 .52
Grb2
KLA  ATP  ATP+KLA
U07617 Grb2 adaptor protein (grb2) mRNA, complete cds. [U07617] KLA .83 .80 .95 1.13 1.38 1.36 1.06
ATP .84 .74 .51 .41 .82 .74 .59
KLA/ATP .77 .70 .57 .54 1.49 1.39 .53
Hras1
KLA  ATP  ATP+KLA
NM_008284 Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] KLA .79 .82 .77 .82 .94 1.03 1.07
ATP 1.01 .95 .69 .83 .79 1.12 1.15
KLA/ATP .84 .77 .61 .65 .82 1.00 1.05
Igh-VJ55
8
KLA  ATP  ATP+KLA
AY547436 immunoglobulin heavy chain VDJ region mRNA, partial cds [AY547436] KLA 1.06 1.05 1.01 .93 1.03 .96 .93
ATP .99 1.00 1.06 .95 .96 1.06 1.05
KLA/ATP .98 .94 1.07 .95 .97 .99 1.02
Igh-VJ55
8
KLA  ATP  ATP+KLA
CA578712 gb|K0727F04-5N NIA Mouse Hematopoietic Stem Cell (Lin- [CA578712] KLA .99 .94 1.01 1.10 .93 .97 .92
ATP .93 1.04 1.01 .98 1.05 .96 .95
KLA/ATP .99 .95 .95 .98 1.02 .98 .95
Igh-VJ55
8
KLA  ATP  ATP+KLA
ENSMUST00000103412 ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHA] [ENSMUST00000103412] KLA 1.01 .97 1.20 1.01 .98 1.44 1.24
ATP .99 .98 1.07 1.03 1.00 1.01 1.21
KLA/ATP .99 1.02 .96 1.03 .97 1.13 1.30
Igh-VJ55
8
KLA  ATP  ATP+KLA
ENSMUST00000103413 ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHE] [ENSMUST00000103413] KLA 1.00 .99 1.06 1.06 .99 1.03 1.02
ATP 1.08 1.06 1.06 1.06 1.02 1.06 .95
KLA/ATP 1.00 1.04 1.09 1.02 1.06 1.02 .95
Igh-VJ55
8
KLA  ATP  ATP+KLA
U39781 J558+ IgM heavy chain mRNA, hybridoma clone ME2B7, partial cds. [U39781] KLA .93 .89 .98 .97 1.03 1.00 .94
ATP 1.04 1.02 1.08 .94 .93 .90 .79
KLA/ATP .88 .89 .97 .93 .88 .92 .82
Il13
KLA  ATP  ATP+KLA
NM_008355 interleukin 13 (Il13), mRNA [NM_008355] KLA 1.08 1.05 .98 1.10 1.01 1.03 1.02
ATP 1.00 .98 1.08 .98 .99 1.05 .97
KLA/ATP .96 .96 1.09 1.02 1.04 1.01 .97
Il3
KLA  ATP  ATP+KLA
NM_010556 interleukin 3 (Il3), mRNA [NM_010556] KLA 1.05 .94 1.01 .99 1.03 1.07 .95
ATP .95 1.03 1.03 .98 .98 .97 .96
KLA/ATP 1.02 1.03 1.02 .94 .97 1.02 1.04
Il4
KLA  ATP  ATP+KLA
NM_021283 interleukin 4 (Il4), mRNA [NM_021283] KLA .94 .95 .91 .94 .91 .94 1.07
ATP 1.02 1.06 1.05 1.22 1.12 1.10 1.26
KLA/ATP .92 .96 .93 1.08 .98 1.03 1.18
Il5
KLA  ATP  ATP+KLA
NM_010558 interleukin 5 (Il5), mRNA [NM_010558] KLA 1.10 1.11 1.10 .98 1.01 .98 .97
ATP .94 1.04 1.08 .92 .97 1.02 1.03
KLA/ATP .98 .92 1.12 1.03 1.02 1.00 1.03
Inpp5d
KLA  ATP  ATP+KLA
NM_010566 inositol polyphosphate-5-phosphatase D (Inpp5d), transcript variant 1, mRNA [NM_010566] KLA .17 .15 .13 .20 .56 1.17 .81
ATP 1.09 1.05 .86 .70 .37 .42 1.25
KLA/ATP .18 .15 .14 .12 .17 .37 1.19
Kras
KLA  ATP  ATP+KLA
NM_021284 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] KLA .53 .49 .40 .42 .49 .95 1.05
ATP .98 1.01 1.16 1.17 1.39 1.29 1.74
KLA/ATP .50 .47 .50 .56 1.00 1.24 1.58
Lat
KLA  ATP  ATP+KLA
NM_010689 linker for activation of T cells (Lat), mRNA [NM_010689] KLA .91 .95 .94 .87 .76 .63 .48
ATP .97 .99 1.01 1.50 1.59 1.49 1.00
KLA/ATP .91 1.04 .93 1.15 1.11 .96 .65
Lcp2
KLA  ATP  ATP+KLA
NM_010696 lymphocyte cytosolic protein 2 (Lcp2), mRNA [NM_010696] KLA 9.10 9.37 9.29 7.53 9.33 5.54 4.23
ATP 1.25 1.38 .95 1.73 2.80 2.13 1.06
KLA/ATP 10.47 10.89 6.89 11.38 3.88 1.80 2.82
Lyn
KLA  ATP  ATP+KLA
NM_010747 Yamaguchi sarcoma viral (v-yes-1) oncogene homolog (Lyn), transcript variant 2, mRNA [NM_010747] KLA 2.48 2.80 3.76 3.81 5.30 4.57 2.46
ATP 1.06 1.18 .82 .97 .74 1.45 1.21
KLA/ATP 2.82 3.16 2.24 2.87 1.73 1.80 2.63
Map2k1
KLA  ATP  ATP+KLA
NM_008927 mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] KLA 1.82 2.00 2.31 2.03 2.51 2.20 1.51
ATP .99 1.14 .81 .87 .90 1.57 1.11
KLA/ATP 1.90 2.03 1.50 1.93 1.63 2.03 2.06
Map2k2
KLA  ATP  ATP+KLA
NM_023138 mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138] KLA .96 1.01 1.09 .99 1.11 1.15 1.42
ATP 1.07 1.05 .74 .86 1.04 1.16 1.21
KLA/ATP 1.14 1.03 .68 .78 .85 1.01 1.20
Map2k3
KLA  ATP  ATP+KLA
NM_008928 mitogen-activated protein kinase kinase 3 (Map2k3), mRNA [NM_008928] KLA .88 .88 .73 .65 .99 1.34 .92
ATP 1.04 1.09 .89 1.62 1.93 1.75 1.17
KLA/ATP 1.00 .92 .66 1.21 1.80 2.24 2.10
Map2k4
KLA  ATP  ATP+KLA
NM_009157 mitogen-activated protein kinase kinase 4 (Map2k4), mRNA [NM_009157] KLA 3.67 3.75 4.23 3.90 3.30 1.87 1.12
ATP 1.05 1.11 1.04 .93 1.16 2.62 1.02
KLA/ATP 3.70 4.13 3.27 4.13 2.98 3.03 1.82
Map2k6
KLA  ATP  ATP+KLA
NM_011943 mitogen-activated protein kinase kinase 6 (Map2k6), mRNA [NM_011943] KLA .68 .67 .64 .67 .62 .59 .61
ATP 1.02 1.12 1.04 1.10 .79 .61 .61
KLA/ATP .73 .69 .71 .74 .66 .62 .98
Map2k7
KLA  ATP  ATP+KLA
BC070467 mitogen activated protein kinase kinase 7, mRNA (cDNA clone MGC:96654 IMAGE:30615302), complete cds [BC070467] KLA .77 .79 .88 .77 .97 .96 1.27
ATP 1.11 1.26 .93 1.19 1.13 1.45 1.16
KLA/ATP .89 .88 .59 .89 .86 1.32 1.28
Map2k7
KLA  ATP  ATP+KLA
NM_001042557 mitogen-activated protein kinase kinase 7 (Map2k7), transcript variant 1, mRNA [NM_001042557] KLA .96 .95 1.02 .96 .95 1.09 1.19
ATP 1.02 1.07 .88 .97 .93 1.10 1.17
KLA/ATP 1.01 .99 .80 .87 .76 1.21 1.16
Mapk1
KLA  ATP  ATP+KLA
NM_001038663 mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] KLA .97 1.03 .93 .86 .79 1.01 1.04
ATP .96 1.18 1.01 1.13 .84 1.04 1.16
KLA/ATP .99 .99 .84 .87 .63 .96 1.26
Mapk1
KLA  ATP  ATP+KLA
NM_011949 mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] KLA .88 .80 .80 .73 .75 .76 .65
ATP .97 .96 1.06 .88 .90 .68 .48
KLA/ATP .82 .81 .78 .65 .64 .64 .45
Mapk10
KLA  ATP  ATP+KLA
AK076990 adult male testis cDNA, RIKEN full-length enriched library, clone:4930597C01 product:mitogen activated protein kinase 10, full insert sequence. [AK076990] KLA 1.03 1.05 .98 1.04 .94 .95 1.02
ATP 1.00 .99 1.06 .97 1.01 .96 .99
KLA/ATP 1.07 1.01 .95 1.05 .82 .95 .87
Mapk10
KLA  ATP  ATP+KLA
NM_009158 mitogen-activated protein kinase 10 (Mapk10), transcript variant 1, mRNA [NM_009158] KLA .95 1.00 .97 1.01 .99 1.01 .95
ATP 1.01 1.02 .98 1.01 1.04 1.01 .99
KLA/ATP 1.05 .99 1.01 .98 .92 .97 .98
Mapk11
KLA  ATP  ATP+KLA
NM_011161 mitogen-activated protein kinase 11 (Mapk11), mRNA [NM_011161] KLA 1.28 1.30 1.41 1.46 1.58 1.29 .98
ATP .96 .95 .89 .82 .79 1.09 .85
KLA/ATP 1.44 1.42 1.32 1.23 1.23 .74 .66
Mapk12
KLA  ATP  ATP+KLA
NM_013871 mitogen-activated protein kinase 12 (Mapk12), mRNA [NM_013871] KLA .94 .86 .87 .81 .77 .68 .49
ATP .97 .83 .92 .90 .86 .90 .51
KLA/ATP .91 .89 .88 .85 1.12 1.14 .53
Mapk13
KLA  ATP  ATP+KLA
NM_011950 mitogen-activated protein kinase 13 (Mapk13), mRNA [NM_011950] KLA 1.22 1.21 1.35 1.26 1.24 1.13 1.01
ATP 1.08 1.00 1.20 1.20 1.13 1.22 1.39
KLA/ATP 1.22 1.27 1.30 1.30 1.21 1.11 1.47
Mapk14
KLA  ATP  ATP+KLA
NM_011951 mitogen-activated protein kinase 14 (Mapk14), mRNA [NM_011951] KLA .70 .70 .62 .54 .67 .88 1.11
ATP 1.03 .98 .87 .69 .48 .78 .66
KLA/ATP .74 .68 .52 .46 .38 .45 .62
Mapk3
KLA  ATP  ATP+KLA
NM_011952 mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] KLA .81 .85 .88 .72 .79 .73 .90
ATP 1.13 1.30 .92 1.48 1.08 .68 1.03
KLA/ATP 1.01 1.01 .66 1.13 .77 .77 1.16
Mapk8
KLA  ATP  ATP+KLA
AK162915 adult male spinal cord cDNA, RIKEN full-length enriched library, clone:A330031O19 product:mitogen activated protein kinase 8, full insert sequence [AK162915] KLA .94 .86 .80 .83 .77 .85 .83
ATP 1.08 1.12 .94 .80 .83 .71 .75
KLA/ATP .83 .81 .80 .74 .74 .75 .67
Mapk8
KLA  ATP  ATP+KLA
AK163829 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130070A06 product:mitogen activated protein kinase 8, full insert sequence [AK163829] KLA .65 .61 .66 .70 .90 1.02 1.03
ATP .99 .94 1.68 1.44 1.75 1.84 1.10
KLA/ATP .63 .67 1.11 1.00 2.01 1.68 1.15
Mapk8
KLA  ATP  ATP+KLA
NM_016700 mitogen-activated protein kinase 8 (Mapk8), mRNA [NM_016700] KLA .96 1.00 .94 .96 .94 .99 1.04
ATP 1.01 1.05 1.01 .99 1.03 .98 1.02
KLA/ATP .96 .97 .96 .97 .93 .94 .96
Mapk9
KLA  ATP  ATP+KLA
NM_016961 mitogen-activated protein kinase 9 (Mapk9), transcript variant 2, mRNA [NM_016961] KLA 1.28 1.37 1.59 1.60 1.61 1.43 1.38
ATP 1.03 .99 .74 .71 .79 1.20 1.01
KLA/ATP 1.53 1.30 1.07 .99 .83 1.10 1.40
Mapk9
KLA  ATP  ATP+KLA
NM_207692 mitogen-activated protein kinase 9 (Mapk9), transcript variant 1, mRNA [NM_207692] KLA 1.39 1.53 1.69 1.69 1.55 1.44 1.51
ATP .95 .92 .75 .85 .70 1.46 1.17
KLA/ATP 1.37 1.35 .99 1.18 .91 1.22 1.62
Mm.21312
8
KLA  ATP  ATP+KLA
141801344 Unknown KLA .96 .95 .83 .77 .52 .99 1.32
ATP .80 .82 1.09 .80 .83 1.19 1.46
KLA/ATP .78 .92 .98 .62 .71 .94 1.41
Mm.25381
9
KLA  ATP  ATP+KLA
118130676 Unknown KLA 1.81 1.88 1.96 1.62 1.89 2.44 1.56
ATP .92 .91 1.24 1.01 1.16 2.06 1.95
KLA/ATP 1.62 1.86 1.86 1.41 1.89 2.37 1.97
Mm.27970
KLA  ATP  ATP+KLA
13994135 Unknown KLA 1.06 1.11 1.16 1.07 1.11 1.08 .95
ATP 1.02 1.09 1.05 1.05 .94 1.16 1.32
KLA/ATP 1.10 1.19 1.11 1.04 1.08 1.02 1.33
Mm.33050
7
KLA  ATP  ATP+KLA
67906182 Unknown KLA .94 .98 .99 1.03 1.05 1.07 .98
ATP .95 1.02 .97 .98 .99 1.05 1.02
KLA/ATP 1.02 1.05 1.01 1.03 .99 .98 .97
Mm.41292
2
KLA  ATP  ATP+KLA
145966829 Unknown KLA 3.65 3.76 3.75 3.79 3.42 1.75 1.10
ATP 1.11 1.17 1.04 .90 1.37 2.90 1.00
KLA/ATP 3.31 3.97 3.38 3.84 3.04 3.31 2.09
Mm.44463
KLA  ATP  ATP+KLA
118129851 Unknown KLA 1.01 .98 .97 1.02 .93 1.06 1.05
ATP .97 1.01 1.04 1.06 1.02 1.08 .97
KLA/ATP 1.02 1.06 .95 1.04 1.09 1.14 1.03
Ms4a2
KLA  ATP  ATP+KLA
NM_013516 membrane-spanning 4-domains, subfamily A, member 2 (Ms4a2), mRNA [NM_013516] KLA 1.02 .96 1.07 1.01 1.04 1.01 .97
ATP 1.03 .97 1.10 1.01 1.00 .96 .96
KLA/ATP .99 .98 .99 .99 1.03 .99 1.00
Nras
KLA  ATP  ATP+KLA
NM_010937 neuroblastoma ras oncogene (Nras), mRNA [NM_010937] KLA 1.20 1.22 1.27 1.20 1.09 .91 .84
ATP .98 .91 .69 .61 .59 .67 .78
KLA/ATP 1.22 1.14 .97 .79 .73 .61 .72
Pdk1
KLA  ATP  ATP+KLA
AK165090 2 days pregnant adult female ovary cDNA, RIKEN full-length enriched library, clone:E330005M21 product:hypothetical protein, full insert sequence. [AK165090] KLA .86 .77 .71 .67 .45 .29 .35
ATP 1.06 .88 1.21 .72 .60 .26 .15
KLA/ATP .81 .74 .97 .57 .51 .22 .09
Pdk1
KLA  ATP  ATP+KLA
NM_172665 pyruvate dehydrogenase kinase, isoenzyme 1 (Pdk1), nuclear gene encoding mitochondrial protein, mRNA [NM_172665] KLA .92 .94 .91 .79 .63 .46 .51
ATP .95 1.03 1.06 1.02 .63 .31 .37
KLA/ATP .88 .91 .91 .89 .62 .31 .27
Pik3ca
KLA  ATP  ATP+KLA
ENSMUST00000108243 ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] KLA 1.07 1.01 .91 .90 .98 .96 .86
ATP 1.03 .87 1.12 .63 1.22 1.86 .60
KLA/ATP 1.05 .82 .91 .61 1.17 1.26 .63
Pik3ca
KLA  ATP  ATP+KLA
NM_008839 phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] KLA 1.15 1.11 1.05 .82 .99 1.03 1.27
ATP .98 1.00 .79 .75 .96 1.32 1.10
KLA/ATP 1.10 .98 .64 .72 .80 1.20 1.41
Pik3cb
KLA  ATP  ATP+KLA
NM_029094 phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] KLA 1.06 1.06 1.03 .73 .68 .98 1.69
ATP 1.04 1.21 .95 1.02 .85 .93 1.73
KLA/ATP 1.15 1.27 .73 .83 .58 .81 1.81
Pik3cd
KLA  ATP  ATP+KLA
NM_008840 phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] KLA 2.28 2.42 3.10 4.17 3.35 2.31 1.34
ATP 1.02 .91 .99 .63 .30 .67 .80
KLA/ATP 2.14 2.23 2.70 1.51 1.17 .85 .72
Pik3cd
KLA  ATP  ATP+KLA
U86587 phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] KLA 2.21 2.24 3.71 3.17 3.67 2.66 1.48
ATP 1.00 1.03 .93 .96 .46 .75 .97
KLA/ATP 2.27 2.32 1.97 2.02 1.01 .99 .98
Pik3cg
KLA  ATP  ATP+KLA
NM_020272 phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] KLA .53 .53 .61 .64 .97 .86 .79
ATP 1.01 1.13 .88 .89 .52 .53 .53
KLA/ATP .58 .53 .43 .60 .40 .43 .62
Pik3r1
KLA  ATP  ATP+KLA
NM_001077495 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] KLA 1.05 1.07 1.03 1.00 1.01 1.20 .85
ATP .97 1.02 1.48 1.42 1.76 1.33 1.23
KLA/ATP 1.11 1.12 1.06 1.17 1.24 .99 1.12
Pik3r2
KLA  ATP  ATP+KLA
NM_008841 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] KLA .50 .50 .48 .43 .46 .66 .75
ATP .78 .68 .45 .43 .28 .57 1.37
KLA/ATP .49 .38 .32 .33 .38 .67 1.10
Pik3r3
KLA  ATP  ATP+KLA
NM_181585 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] KLA 1.59 1.49 1.37 1.17 1.05 1.55 1.41
ATP 1.12 1.00 1.33 1.70 2.01 2.37 2.02
KLA/ATP 1.63 1.54 1.58 1.70 2.43 2.68 1.92
Pik3r5
KLA  ATP  ATP+KLA
NM_177320 phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] KLA 3.57 3.58 4.16 3.54 4.11 2.59 2.39
ATP 1.08 1.08 .93 1.67 3.11 1.88 1.34
KLA/ATP 3.91 3.70 3.30 3.80 2.70 2.04 3.00
Pla2g4a
KLA  ATP  ATP+KLA
NM_008869 phospholipase A2, group IVA (cytosolic, calcium-dependent) (Pla2g4a), mRNA [NM_008869] KLA 3.93 4.49 4.86 6.40 6.44 3.10 1.68
ATP 1.13 1.36 1.27 1.30 1.02 5.37 1.47
KLA/ATP 3.64 4.45 4.76 7.11 2.96 4.08 2.60
Pla2g4b
KLA  ATP  ATP+KLA
NM_145378 phospholipase A2, group IVB (cytosolic) (Pla2g4b), mRNA [NM_145378] KLA 1.09 1.18 .95 1.01 .97 .97 .77
ATP 1.05 1.14 1.28 .94 .88 1.18 .70
KLA/ATP 1.23 1.43 1.21 1.02 1.15 1.16 .78
Pla2g4c
KLA  ATP  ATP+KLA
AK145339 1 cell embryo 1 cell cDNA, RIKEN full-length enriched library, clone:I0C0013F18 product:weakly similar to Cytosolic phospholipase A2 gamma [Homo sapiens], full insert sequence [AK145339] KLA 1.09 1.21 1.33 1.17 1.26 1.30 1.05
ATP .97 1.06 1.00 .98 .98 .98 1.05
KLA/ATP 1.19 1.16 1.18 1.13 1.04 1.02 1.06
Pla2g4c
KLA  ATP  ATP+KLA
NM_001004762 phospholipase A2, group IVC (cytosolic, calcium-independent) (Pla2g4c), mRNA [NM_001004762] KLA .93 1.00 .94 .93 .94 .94 .96
ATP .98 .96 1.13 .97 .99 .89 .96
KLA/ATP 1.01 1.01 1.07 1.01 .94 1.01 .92
Pla2g4e
KLA  ATP  ATP+KLA
AK049063 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230096D22 product:hypothetical Lysophospholipase catalytic domain containing protein, full insert sequence. [AK049063] KLA 1.03 1.09 1.01 1.01 1.06 .94 1.05
ATP 1.03 1.00 1.06 1.01 .96 1.05 1.05
KLA/ATP .98 1.00 1.01 .98 1.03 .95 1.01
Pla2g4e
KLA  ATP  ATP+KLA
NM_177845 phospholipase A2, group IVE (Pla2g4e), mRNA [NM_177845] KLA .97 .95 1.01 .97 1.02 1.03 1.05
ATP .98 .99 1.00 1.10 .98 1.00 1.02
KLA/ATP 1.05 .93 .96 1.03 1.08 1.05 .99
Pla2g4f
KLA  ATP  ATP+KLA
NM_001024145 phospholipase A2, group IVF (Pla2g4f), mRNA [NM_001024145] KLA 1.08 .99 1.04 1.02 1.04 .98 1.01
ATP .99 1.04 .99 1.03 1.12 1.01 1.25
KLA/ATP .97 1.04 1.10 1.06 1.04 1.03 1.03
Plcg2
KLA  ATP  ATP+KLA
NM_172285 phospholipase C, gamma 2 (Plcg2), mRNA [NM_172285] KLA .76 .74 .68 .66 .71 .92 .95
ATP .96 .90 .95 .87 .81 .79 .91
KLA/ATP .76 .71 .69 .62 .72 .78 .68
Prkca
KLA  ATP  ATP+KLA
NM_011101 protein kinase C, alpha (Prkca), mRNA [NM_011101] KLA 1.00 .96 .94 .95 .95 .89 .96
ATP 1.00 1.03 .91 .94 .82 .87 1.13
KLA/ATP 1.02 .95 .91 .86 .78 .84 .94
Prkcb1
KLA  ATP  ATP+KLA
NM_008855 protein kinase C, beta 1 (Prkcb1), mRNA [NM_008855] KLA .92 .95 .93 .78 .77 1.08 1.83
ATP 1.03 1.12 1.09 1.23 .90 2.08 .96
KLA/ATP .98 .99 .82 .89 .62 1.01 1.08
Prkcd
KLA  ATP  ATP+KLA
NM_011103 protein kinase C, delta (Prkcd), mRNA [NM_011103] KLA 1.72 1.84 1.90 1.68 2.01 1.61 1.64
ATP 1.00 1.03 .68 .81 1.38 1.26 .98
KLA/ATP 1.77 1.79 1.16 1.19 1.33 1.25 1.56
Prkce
KLA  ATP  ATP+KLA
AK017901 adult male thymus cDNA, RIKEN full-length enriched library, clone:5830406C15 product:unclassifiable, full insert sequence. [AK017901] KLA 1.63 1.44 1.95 2.09 1.96 1.34 1.56
ATP .99 .83 .85 .78 .85 2.44 1.47
KLA/ATP 1.36 1.45 1.44 1.23 1.30 2.39 2.29
Prkce
KLA  ATP  ATP+KLA
AK042994 7 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:A730046G04 product:protein kinase C, epsilon, full insert sequence. [AK042994] KLA 1.01 1.07 1.03 1.03 1.04 1.00 1.06
ATP .99 1.09 1.08 1.05 1.02 1.06 1.07
KLA/ATP 1.00 .90 1.06 1.14 1.10 1.08 1.09
Rac1
KLA  ATP  ATP+KLA
NM_009007 RAS-related C3 botulinum substrate 1 (Rac1), mRNA [NM_009007] KLA 1.02 1.01 1.02 .99 1.03 1.15 1.08
ATP .99 1.15 1.01 1.27 1.06 1.20 1.06
KLA/ATP 1.00 1.04 .88 1.16 .91 1.21 1.38
Rac2
KLA  ATP  ATP+KLA
NM_009008 RAS-related C3 botulinum substrate 2 (Rac2), mRNA [NM_009008] KLA 1.55 1.68 1.86 2.15 3.36 3.59 3.74
ATP 1.13 1.16 .74 .99 .84 .91 1.66
KLA/ATP 1.59 1.71 1.19 1.56 1.21 1.60 3.48
Rac3
KLA  ATP  ATP+KLA
NM_133223 RAS-related C3 botulinum substrate 3 (Rac3), mRNA [NM_133223] KLA 2.03 2.20 2.64 2.18 2.95 2.29 1.41
ATP 1.02 1.12 .94 1.42 1.16 .84 .87
KLA/ATP 2.30 2.32 1.57 2.55 1.75 1.47 1.61
Raf1
KLA  ATP  ATP+KLA
AK036317 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] KLA 1.47 1.34 1.55 1.29 1.59 1.32 1.46
ATP 1.05 .98 .54 .63 3.32 2.07 1.01
KLA/ATP 1.57 1.33 .79 .96 2.26 1.38 1.35
Raf1
KLA  ATP  ATP+KLA
NM_029780 v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] KLA 1.65 1.64 1.93 1.77 1.77 1.72 1.81
ATP .95 .96 .83 .80 2.22 2.92 1.19
KLA/ATP 1.68 1.64 1.39 1.32 1.85 2.50 2.06
Sos1
KLA  ATP  ATP+KLA
NM_009231 Son of sevenless homolog 1 (Drosophila) (Sos1), mRNA [NM_009231] KLA 2.36 2.40 3.42 3.15 2.78 1.81 1.71
ATP .99 1.00 .99 1.15 1.14 1.25 1.24
KLA/ATP 2.41 2.26 1.95 2.44 1.47 1.66 1.37
Sos2
KLA  ATP  ATP+KLA
XM_127051 gb|PREDICTED: Mus musculus Son of sevenless homolog 2 (Drosophila) (Sos2), mRNA [XM_127051] KLA .81 .77 .79 .92 1.04 1.06 1.20
ATP 1.00 1.00 1.09 .79 .68 .81 .94
KLA/ATP .77 .69 .71 .60 .64 .77 1.07
Syk
KLA  ATP  ATP+KLA
NM_011518 spleen tyrosine kinase (Syk), mRNA [NM_011518] KLA 2.48 2.59 2.57 2.26 3.29 3.75 3.19
ATP .96 .85 .59 1.01 2.80 3.77 2.11
KLA/ATP 2.56 2.09 1.16 1.35 2.50 4.33 5.10
Tnf
KLA  ATP  ATP+KLA
NM_013693 tumor necrosis factor (Tnf), mRNA [NM_013693] KLA 13.35 12.76 10.71 9.03 10.64 7.39 8.32
ATP 2.01 2.48 8.27 19.20 9.72 4.09 1.49
KLA/ATP 12.72 15.76 12.73 17.34 5.10 3.61 6.07
Vav1
KLA  ATP  ATP+KLA
NM_011691 vav 1 oncogene (Vav1), mRNA [NM_011691] KLA .79 .83 .98 1.17 1.97 2.42 2.26
ATP 1.06 1.02 .88 1.01 1.34 .82 1.36
KLA/ATP .88 .85 .73 .78 1.25 1.47 2.17
Vav2
KLA  ATP  ATP+KLA
BC053060 vav 2 oncogene, mRNA (cDNA clone MGC:62363 IMAGE:5704852), complete cds [BC053060] KLA .73 .58 .55 1.16 .76 1.35 1.75
ATP .99 .89 .79 .82 .67 .85 1.09
KLA/ATP .64 .63 .61 .65 .66 .80 1.23
Vav2
KLA  ATP  ATP+KLA
NM_009500 vav 2 oncogene (Vav2), mRNA [NM_009500] KLA .98 1.05 .98 .99 1.02 1.36 1.43
ATP 1.07 1.06 .96 1.01 .89 .95 1.08
KLA/ATP 1.04 1.05 .98 1.03 .88 .99 1.13
Vav3
KLA  ATP  ATP+KLA
NM_020505 vav 3 oncogene (Vav3), transcript variant 1, mRNA [NM_020505] KLA .95 .94 .86 .87 .82 .66 .56
ATP 1.06 1.09 .81 1.05 .80 .75 .85
KLA/ATP 1.00 .84 .62 .85 .74 .56 .74